Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Assessment of the pain patients with the multiple sclerosis after applying the physiotherapy treatment].
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Getting a Handle on Lymphopenia With Tecfidera
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Multiple sclerosis: A lifestyle disease?
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
A Unified Frequency Domain Model to Study the Effect of Demyelination on Axonal Conduction.
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Central fatigue in multiple sclerosis: a review of the literature.
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
The impact of multiple sclerosis relapse treatment on migration of effector T cells - Preliminary study.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Emerging oral agents for multiple sclerosis.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.

Pages